6-硝基藜芦酸甲酯 | 26791-93-5

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 6-硝基藜芦酸甲酯
• 中文别名: 4,5-二甲氧基-2-硝基苯甲酸甲酯
• 英文名称: methyl 4,5-dimethoxy-2-nitrobenzoate
• 英文别名: 3,4-dimethoxy-6-nitrobenzoic acid,methyl ester
• CAS: 26791-93-5
• 化学式: C₁₀H₁₁NO₆
• mdl: MFCD00007239
• 分子量: 241.2
• InChiKey: SYYKLKHBZGFKOC-UHFFFAOYSA-N

物化性质

• 熔点：
  141-144 °C(lit.)
• 沸点：
  381.4±37.0 °C(Predicted)
• 密度：
  1.288±0.06 g/cm3(Predicted)
• 稳定性/保质期：
  如果按照规格正确使用和储存，则不会分解，请避免接触氧化物。

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  90.6
• 氢给体数：
  0
• 氢受体数：
  6

安全信息

• TSCA：
  Yes
• 安全说明：
  S22,S24/25
• WGK Germany：
  3
• 危险品标志：
  Xi
• 储存条件：
  将贮藏器密封，并将其放入一个紧密封装的容器中。存放在阴凉、干燥处。

SDS

Name:	Methyl 4,5-dimethoxy-2-nitrobenzoate, 97% Material Safety Data Sheet
Synonym:
CAS:	26791-93-5

Section 1 - Chemical Product MSDS Name: Methyl 4,5-dimethoxy-2-nitrobenzoate, 97% Material Safety Data Sheet
Synonym:

---

SECTION 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
26791-93-5	Methyl 4,5-dimethoxy-2-nitrobenzoate	97%	248-008-5

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

SECTION 3 - HAZARDS IDENTIFICATION EMERGENCY OVERVIEW Not available. Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

SECTION 4 - FIRST AID MEASURES
Eyes:
Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

SECTION 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

SECTION 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

SECTION 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

SECTION 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low. Exposure Limits CAS# 26791-93-5: Personal Protective Equipment
Eyes:
Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

SECTION 9 - PHYSICAL AND CHEMICAL PROPERTIES
Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 141 - 144 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H11NO6
Molecular Weight: 241

---

SECTION 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, reducing agents, strong acids.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide, acrid smoke and fumes.
Hazardous Polymerization: Has not been reported

---

SECTION 11 - TOXICOLOGICAL INFORMATION RTECS#: CAS# 26791-93-5 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Methyl 4,5-dimethoxy-2-nitrobenzoate - Not listed by ACGIH, IARC, or NTP.

---

SECTION 12 - ECOLOGICAL INFORMATION

---

SECTION 13 - DISPOSAL CONSIDERATIONS Dispose of in a manner consistent with federal, state, and local regulations.

---

SECTION 14 - TRANSPORT INFORMATION IATA No information available. IMO No information available. RID/ADR No information available.

---

SECTION 15 - REGULATORY INFORMATION European/International Regulations European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases: S 24/25 Avoid contact with skin and eyes. WGK (Water Danger/Protection) CAS# 26791-93-5: No information available. Canada CAS# 26791-93-5 is listed on Canada's NDSL List. CAS# 26791-93-5 is not listed on Canada's Ingredient Disclosure List. US FEDERAL TSCA CAS# 26791-93-5 is listed on the TSCA inventory.

---

SECTION 16 - ADDITIONAL INFORMATION
MSDS Creation Date: 6/10/2003 Revision #0 Date: Original. The information above is believed to be accurate and represents the best information currently available to us. However, we make no warranty of merchantability or any other warranty, express or implied, with respect to such information, and we assume no liability resulting from its use. Users should make their own investigations to determine the suitability of the information for their particular purposes. In no way shall the company be liable for any claims, losses, or damages of any third party or for lost profits or any special, indirect, incidental, consequential or exemplary damages, howsoever arising, even if the company has been advised of the possibility of such damages.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途：用于制作医药中间体。

反应信息

• 作为反应物：
  描述：

  6-硝基藜芦酸甲酯 在 ammonium acetate 、 水 、 potassium carbonate 、 tin(ll) chloride 、 sodium hydroxide 作用下， 以 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 52.0h， 生成 6-苄氧基-7-甲氧基喹唑啉-4-酮
  参考文献：
  名称：

  含氟6,7-二烷氧基联芳基的磷酸二酯酶10 A抑制剂：抑制力，选择性和代谢的合成和体外评估。

  摘要：

  基于有效的磷酸二酯酶10 A（PDE10A）抑制剂PQ-10，我们合成了32种衍生物，以确定其分子结构与结合特性之间的关系。评估了它们作为潜在的正电子发射断层扫描（PET）配体的作用，以及它们对PDE10A和其他PDE的抑制能力，并在体外确定了它们的代谢稳定性。根据我们的发现，喹唑啉部分2位的卤代烷基取代基和/或6位或7位的卤代烷氧基取代基不仅影响化合物的亲和力，而且还影响其对PDE10A的选择性。由于在喹唑啉环的6位上用甲氧基取代了单氟乙氧基或二氟乙氧基，PDE10A相对于PDE3A的选择性增加了。通过6获得相同的结果 喹喔啉部分上的7-二氟取代。最后，氟化物（R）-7-（氟甲氧基）-6-甲氧基-4-（3-（喹喔啉-2-基氧基）吡咯烷-1-基）喹唑啉（16 a），19 a - d，（R）-叔丁基- 3-（6-氟喹喔啉-2-基氧基）吡咯烷-1-羧酸酯（29）和35（IC 50 PDE10A

  DOI：

  10.1002/cmdc.201300522
• 作为产物：
  描述：

  香草酸甲酯 在 硝酸 、 potassium carbonate 、 溶剂黄146 作用下， 以 丙酮 为溶剂， 生成 6-硝基藜芦酸甲酯
  参考文献：
  名称：

  Benzamides and benzamidines as specific inhibitors of epidermal growth factor receptor and v-Src protein tyrosine kinases

  摘要：

  The benzamides 1 and the benzamidines 2 as well as the cyclic benzamidines 3 were designed and synthesized as the mimics of 4-anilinoquinazolines for an inhibitor of EGFR tyrosine kinase. The specific inhibitions of EGFR tyrosine kinase were observed in the benzamides 1c and 1d, and the benzamidine 2a, whereas the specific inhibitions of v-Src kinase were observed in the benzamide 1j and the benzamidine 2d at a 10 mug/mL concentration of compounds. The cyclic benzamidines 3a and 3b showed potent kinase inhibition of EGFR at a 1.0 mug/mL concentration. According to the docking simulation using the X-ray structure of EGFR kinase domain in complex with erlotimb, the LigScore2 scoring function value of erlotimb was calculated as 5.61, whereas that of the benzamide 1c was 5.05. In a similar manner, the LigScore2 value of the cyclic benzamidine 3a was calculated as 5.10. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.04.030

文献信息

• Bicyclic heterocycles, medicaments containing these compounds, their use and process for preparing them
  申请人：Himmelsbach Frank

  公开号：US20090306105A1

  公开（公告）日：2009-12-10

  The present invention relates to bicyclic heterocycles of the general formula (I), their tautomers, their stereoisomers, their mixtures and their salts, in particular physiologically tolerable salts with inorganic or organic acids, which have valuable pharmacological properties, in particular an inhibiting action on the signal transduction transmitted by tyrosinekinases, their use for the treatment of illnesses, in particular tumours and also benign prostatic hyperplasia (BPH), of disorders of the lungs and the bronchia and their preparation.

  本发明涉及一般式（I）的双环杂环化合物，它们的互变异构体、立体异构体、混合物和盐，特别是与无机或有机酸形成的生理耐受盐，具有有价值的药理特性，特别是对酪氨酸激酶传导的抑制作用，它们用于治疗疾病，特别是肿瘤和良性前列腺增生（BPH），肺部和支气管疾病以及它们的制备。
• 3-Alkoxy-thianapthene-2-carboxamides
  申请人：Societe d'Etudes Scientifiques et Industrielles de l'Ile-de-France

  公开号：US03954748A1

  公开（公告）日：1976-05-04

  The 3-alkoxy-thianaphthene-2-carboxamides of this invention are effective for the treatment of mammals afflicted with emesis. When administered to dogs in dosages of 250 .mu.g/kg, compounds of this invention give 100% protection against vomiting normally induced by subcutaneous administration of apomorphine. The compounds of this invention also favorably modify behavior disturbances in mammals.

  这项发明的3-烷氧基噻吩并2-羧酰胺对患有呕吐症的哺乳动物有效。当以250微克/千克的剂量给狗服用时，这项发明的化合物可使狗免受皮下注射阿波莫啡引起的呕吐，保护效果达到100%。这项发明的化合物还有助于改善哺乳动物的行为紊乱。
• AN EXPEDITIOUS, PRACTICAL LARGE SCALE SYNTHESIS OF 4-AMINO-2-CHLORO-6,7-DIMETHOXYQUINAZOLINAZOLINE
  作者：G. Kumaraswamy、Nivedita Jena、M. N. V. Sastry、B. Ashok Kumar

  DOI：10.1080/00304940409458676

  日期：2004.8

  converted to 8 by treatment with anhydrous ammonia at ambient temperature in dilute THF. In connection with our process development of (f)-doxazocin mesylate," we had an opportunity to evaluate the synthesis of 8. Three major challenges were encountered in course of reproducing the above synthetic route: (i) oxidation of vanillin (1) to vaniliic acid (2) using traditional methods such as KOH melt5 or

  带有各种取代基的喹唑啉因其各种生物学特性而受到极大关注。目前用于治疗高血压的喹唑啉家族的重要药物是普鲁佐星、多沙唑星、四唑星、布那唑星、奈达唑嗪、后唑嗪和阿夫唑星。4-氨基-2-氯-6,7-二甲氧基喹唑啉 (8) 是这些通用抗高血压药物的常见前体。用于制备 4-氨基-2-氯-6,7-二甲氧基喹唑啉 (8) 的出版物*和随后的专利 3 信息涉及取代邻氨基苯甲酸或其酰胺与氰酸钠悬浮液的反应，然后用碱或酸得到取代的 2,4-二羟基喹唑啉 6。 6 与五氯化磷和三氯氧化磷在回流下反应生成 2,4-二氯-6，7-二甲氧基喹唑啉 (7)，通过在室温下在稀 THF 中用无水氨处理将其转化为 8。结合我们的 (f)-doxazocin mesylate 工艺开发，我们有机会评估 8 的合成。在再现上述合成路线的过程中遇到了三个主要挑战：(i) 将香草醛 (1) 氧化为香草酸 (2) 使用传统方法，例如 KOH
• [EN] STEROIDAL ANTI-HORMONE HYBRIDS<br/>[FR] HYBRIDES ANTI-HORMONAUX STÉROÏDIENS
  申请人：UNIV NORTHEASTERN

  公开号：WO2010085747A1

  公开（公告）日：2010-07-29

  Disclosed are novel compounds and compositions for inhibition of androgen and estrogen receptor signaling, methods for inhibiting androgen signaling, methods for inhibiting estrogen signaling, methods for inhibiting the interaction between a co-regulatory protein and an androgen or estrogen receptor, and methods for treating cancer.

  披露了新颖的化合物和组合物，用于抑制雄激素和雌激素受体信号传导，抑制雄激素信号传导的方法，抑制雌激素信号传导的方法，抑制共调节蛋白与雄激素或雌激素受体之间相互作用的方法，以及治疗癌症的方法。
• BICYCLIC HETEROCYCLES, DRUGS CONTAINING SAID COMPOUNDS, USE THEREOF, AND METHOD FOR PRODUCTION THEREOF
  申请人：Himmelsbach Frank

  公开号：US20100022505A1

  公开（公告）日：2010-01-28

  The present invention relates to bicyclic heterocycles of general formula wherein R a , R b and R c are defined as in claim 1 , their tautomers, their stereoisomers, their mixtures and their salts, in particular their physiologically acceptable salts with inorganic or organic acids and bases, which have valuable pharmacological properties, in particular an inhibitory action on the signal transduction mediated by tyrosine kinases, their use for the treatment of illnesses, in particular of tumoral diseases and of benign prostatic hyperplasia (BPH), of diseases of the lung and of the airways, and the preparation thereof.

  本发明涉及一般式的双环杂环化合物 其中 R a ，R b 和R c 如权利要求中所定义， 它们的互变异构体，立体异构体，混合物和盐，特别是它们与无机或有机酸和碱形成的生理上可接受的盐，具有有价值的药理特性，特别是对酪氨酸激酶介导的信号传导具有抑制作用，它们用于治疗疾病，特别是肿瘤性疾病和良性前列腺增生（BPH），肺部和气道疾病，以及其制备。

表征谱图